al002
mAbexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2018 (NCT03635047)
Timeline
Indications
Mechanism of action
TREM2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05744401 | Phase 2 | Jan 4, 2023 | AbbVie, Alector Inc. |
| NCT04592874 | Phase 2 | Nov 30, 2020 | AbbVie, Alector Inc. |
| NCT03635047 | Phase 1 | Nov 30, 2018 | Alector Inc., Nucleus Network Ltd |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alector Inc. | For profit | 3 | 3 | 2 | 2018 |
| AbbVie | For profit | 2 | 0 | 1 | 2020 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1